An in vitro investigation of photodynamic efficacy of FosPegr on human colon cancer cells

Ricky W. K. Wu; Ellie S. M. Chu; Zheng Huang; Malini C. Olivo; David C. W. Ip; Christine M. N. Yow

doi:10.1142/s1793545815500273

[1] D. Cunningham, W. Atkin, H. J. Lenz, H. T. Lynch, B. Minsky, B. Nordlinger, N. Starling, "Colorectal cancer," Lancet 375(9719), 1030–1047 (2010).

[2] A. J. Watson, P. D. Collins, "Colon cancer: A civilization disorder," Dig. Dis. 29(2), 222–228 (2011).

[3] G. Wilkes, K. Hartshorn, "Colon, rectal, and anal cancers," Semin. Oncol. Nurs. 25(1), 32–47 (2009).

[4] M. R. Dixon, M. J. Stamos, "Strategies for palliative care in advanced colorectal cancer," Dig. Surg. 21 (5–6), 344–351 (2004).

[5] A. E. O'Connor, W. M. Gallagher, A. T. Byrne, "Porphyrin and nonporphyrin photosensitizers in oncology: Preclinical and clinical advances in photodynamic therapy," Photochem. Photobiol. 85(5), 1053–1074 (2009).

[6] T. Reynolds, "Photodynamic therapy expands its horizons," J. Natl. Cancer Inst. 89(2), 112–114 (1997).

[7] P. Agostinis, K. Berg, K. A. Cengel, T. H. Foster, A. W. Girotti, S. O. Gollnick, S. M. Hahn, M. R. Hamblin, A. Juzeniene, D. Kessel, M. Korbelik, J. Moan, P. Mroz, D. Nowis, J. Piette, B. C. Wilson, J. Golab, "Photodynamic therapy of cancer: An update," CA Cancer J. Clin. 61(4), 250–281 (2011).

[8] M. B. Vrouenraets, G. W. Visser, G. B. Snow, G. A. van Dongen, "Basic principles, applications in oncology and improved selectivity of photodynamic therapy," Anticancer Res. 23(1B), 505–522 (2003).

[9] B. C. Wilson, "Photodynamic therapy for cancer: Principles," Can. J. Gastroenterol. 16(6), 393–396 (2002).

[10] M. O. Senge, J. C. Brandt, "Temoporfin (Foscan (R), 5,10,15,20-tetra(m-hydroxyphenyl)chlorin) — a second-generation photosensitizer," Photochem. Photobiol. 87(6), 1240–1296 (2011).

[11] M. J. Bovis, J. H. Woodhams, M. Loizidou, D. Scheglmann, S. G. Bown, A. J. Macrobert, "Improved in vivo delivery of m-THPC via pegylated liposomes for use in photodynamic therapy," J. Control Release 157(2), 196–205 (2012).

[12] M. O. Senge, "mTHPC — a drug on its way from second to third generation photosensitizer " Photodiagnosis Photodyn. Ther. 9(2), 170–179 (2012).

[13] T. Reuther, A. C. Kubler, U. Zillmann, C. Flechtenmacher, H. Sinn, "Comparison of the in vivo ef- ficiency of photofrin II-, mTHPC-, mTHPC-PEGand mTHPCnPEG-mediated PDT in a human xenografted head and neck carcinoma," Lasers Surg. Med. 29(4), 314–322 (2001).

[14] R. W. Wu, E. S. Chu, Z. Huang, C. S. Xu, C. W. Ip, C. M. Yow, "FosPegr PDT alters the EBV miRNAs and LMP1 protein expression in EBV positive nasopharyngeal carcinoma cells," J. Photochem. Photobiol. B. 127C, 114–122 (2013).

[15] M. G. Bredell, E. Besic, C. Maake, H. Walt, "The application and challenges of clinical PD-PDT in the head and neck region: A short review," J. Photochem. Photobiol. B. 101(3), 185–190 (2010).

[16] C. A. Robertson, D. H. Evans, H. Abrahamse, "Photodynamic therapy (PDT): A short review on cellular mechanisms and cancer research applications for PDT," J. Photochem. Photobiol. B 96(1), 1–8 (2009).

[17] G. Sherifa, M. A. Saad Zaghloul, O. F. Elsayed, A. Rueck, R. Steiner, A. I. Abdelaziz, M. H. Abdel- Kader, "Functional characterization of Fospeg, and its impact on cell cycle upon PDT of Huh7 hepatocellular carcinoma cell model," Photodiagnosis Photodyn. Ther. 10(1), 87–94 (2013).